Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A

J Pediatr. 2021 Jul:234:212-219.e3. doi: 10.1016/j.jpeds.2021.02.071. Epub 2021 Mar 4.

Abstract

Objectives: To evaluate the applicability and compliance with guidelines for early initiation of long-term prophylaxis in infants with severe hemophilia A and to identify factors associated with guideline compliance.

Study design: This real-world, prospective, multicenter, population-based FranceCoag study included almost all French boys with severe hemophilia A, born between 2000 and 2009 (ie, after guideline implementation).

Results: We included 333 boys in the study cohort. The cumulative incidence of long-term prophylaxis use was 61.2% at 3 years of age vs 9.5% in a historical cohort of 39 boys born in 1996 (ie, before guideline implementation). The guidelines were not applicable in 23.1% of patients due to an early intracranial bleeding or inhibitor development. Long-term prophylaxis was delayed in 10.8% of patients. In the multivariate analysis, 2 variables were significantly associated with "timely long-term prophylaxis" as compared with "delayed long-term prophylaxis": hemophilia treating center location in the southern regions of France (OR 23.6, 95% CI 1.9-286.7, P = .013 vs Paris area) and older age at long-term prophylaxis indication (OR 7.2 for each additional year, 95% CI 1.2-43.2, P = .031). Long-term prophylaxis anticipation was observed in 39.0% of patients. Earlier birth year (OR 0.5, 95% CI 0.3-0.8, P = .010 for birth years 2005-2009 vs 2000-2004) and age at first factor replacement (OR 1.9 for each additional year, 95% CI 1.2-3.0, P = .005) were significantly associated with "long-term prophylaxis guideline compliance" vs "long-term prophylaxis anticipation."

Conclusions: This study suggests that long-term prophylaxis guidelines are associated with increased long-term prophylaxis use. However, early initiation of long-term prophylaxis remains a challenge.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Blood Coagulation Factors / administration & dosage*
  • Blood Coagulation Factors / therapeutic use
  • Child, Preschool
  • Drug Administration Schedule
  • France
  • Guideline Adherence / statistics & numerical data*
  • Hemophilia A / complications*
  • Humans
  • Infant
  • Infant, Newborn
  • Joint Diseases / etiology
  • Joint Diseases / prevention & control*
  • Kaplan-Meier Estimate
  • Logistic Models
  • Male
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians' / standards
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Severity of Illness Index

Substances

  • Blood Coagulation Factors